20% of patients had a best clinical response of SD Elotuzumab (HuLuc63), a humanized mAb CS1 High expression on the surface of MM cell lines and on plasma cells from MM patients 24 ADCC against MM ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...

1 Multiple myeloma originates in blood plasma cells — a type of cell found in bone marrow that is responsible for making antibodies. When these plasma cells become cancerous, they multiply ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized trispecific antibody that targets ...

Multiple myeloma (MM) is a life-threatening hematological ... This review will focus on MM antigens and their specific antibodies. These monoclonal antibodies are an attractive therapeutic tool ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma cells ...

SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both China and the U.S. SIM0500 is a humanized trispecific antibody that targets ...